Evaluation of Etiology, Diagnosis, Treatment and Follow-up Results of Patients With Epilepsy Under the Age of Two


Üstebay D. Ü., Aykol D., Gök A., Soydemir D., Giray Bozkaya Ö., Çağlayan A. O., ...Daha Fazla

15th European Paediatric Neurology Society Congress, Praha, Çek Cumhuriyeti, 20 - 24 Haziran 2023, ss.269

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Praha
  • Basıldığı Ülke: Çek Cumhuriyeti
  • Sayfa Sayıları: ss.269
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: Although many etiological causes (genetic, structural, metabolic) have been identified for epilepsies starting underage of two years, a clear etiology cannot be determined in significant part of patients. Imaging and genetic-based studies in the early stages of life have a very important role in the etiology of epilepsy Methods: Patients diagnosed with epilepsy under age of two between 2011-2016 and 2016-2021 in the Department of Child Neurology at Dokuz Eylül University were evaluated. Etiologies, seizure types, follow-up, treatment and prognosis of the patients were determined retrospectively from archive files. Patients with febrile, symptomatic and single afebrile seizures were not included in the study. Results: The number of patients in Group1 was 328 and the number of patients in Group2 was 327. When evaluated in terms of the etiology of epilepsy, structural abnormalities were significantly higher in Group1 (Group1 n=113, Group2 n=98 p<0.05). In terms of the initial seizure type , the rate of focal seizures was higher in Group1, and generalized seizures were higher in Group2 (Group1: focal seizure n= 109, generalized seizure n=188; Group2: focal seizure n=71, generalized seizure n=256 p<0.05). Control of seizures with a single antiseizure drug was higher in Group2 (Group2 n=127, Group1 n=117, p<0.05). Neuromotor developmental retardation at the time of diagnosis (Group1 n=194, Group2 n=161, p<0.05) and mortality rates were significantly higher in Group1. The most common choice of antiseizure drug was phenobarbital between 2011 and 2016 and levetiracetam between 2016-2021. In Group 1, 7.3% (n=24) of the patients had a genetic diagnosis before 2016. In Group 2, the percent of patients with a specific genetic diagnosis was 10.7% (n=35). Conclusions: The results of our study showed that the etiology, seizure classification and antiseizure drug choice changed over time. We suggest that this may be due to medical and treatment advances in medicine. Keywords: childhood, epilepsy, anti-seizure medication, prognosis